A new day for human challenge trials?

Two years into the coronavirus disease 2019 (COVID-19) pandemic and following several hot debates, the world’s first COVID-19 human challenge trial has recently been published by Killingley et al. We review its findings and explain why this particular juncture in time makes additional challenge tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohrig, Abie, Eyal, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124157/
https://www.ncbi.nlm.nih.gov/pubmed/35610124
http://dx.doi.org/10.1016/j.molmed.2022.05.002
_version_ 1784711685595987968
author Rohrig, Abie
Eyal, Nir
author_facet Rohrig, Abie
Eyal, Nir
author_sort Rohrig, Abie
collection PubMed
description Two years into the coronavirus disease 2019 (COVID-19) pandemic and following several hot debates, the world’s first COVID-19 human challenge trial has recently been published by Killingley et al. We review its findings and explain why this particular juncture in time makes additional challenge trials for COVID-19 and for other diseases justified and important.
format Online
Article
Text
id pubmed-9124157
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-91241572022-05-23 A new day for human challenge trials? Rohrig, Abie Eyal, Nir Trends Mol Med Spotlight Two years into the coronavirus disease 2019 (COVID-19) pandemic and following several hot debates, the world’s first COVID-19 human challenge trial has recently been published by Killingley et al. We review its findings and explain why this particular juncture in time makes additional challenge trials for COVID-19 and for other diseases justified and important. Elsevier Ltd. 2022-07 2022-05-22 /pmc/articles/PMC9124157/ /pubmed/35610124 http://dx.doi.org/10.1016/j.molmed.2022.05.002 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Spotlight
Rohrig, Abie
Eyal, Nir
A new day for human challenge trials?
title A new day for human challenge trials?
title_full A new day for human challenge trials?
title_fullStr A new day for human challenge trials?
title_full_unstemmed A new day for human challenge trials?
title_short A new day for human challenge trials?
title_sort new day for human challenge trials?
topic Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124157/
https://www.ncbi.nlm.nih.gov/pubmed/35610124
http://dx.doi.org/10.1016/j.molmed.2022.05.002
work_keys_str_mv AT rohrigabie anewdayforhumanchallengetrials
AT eyalnir anewdayforhumanchallengetrials
AT rohrigabie newdayforhumanchallengetrials
AT eyalnir newdayforhumanchallengetrials

Ejemplares similares